Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isoflavones-TNO refers to a specific formulation of isoflavone-enriched foods developed and studied by TNO (Netherlands Organisation for Applied Scientific Research) for the management of postmenopausal health. These isoflavones, which are phytoestrogens typically derived from soy (such as genistein and daidzein), act as selective estrogen receptor modulators (SERMs). They are investigated for their potential to mitigate bone mineral density loss and regulate bone turnover in early postmenopausal women. By binding to estrogen receptors, these compounds aim to provide a dietary alternative to traditional hormone replacement therapy (HRT) for preventing osteoporosis and managing hormonal status during the menopausal transition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoflavones-TNO.